Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$1.53 USD
-0.16 (-9.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.54 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TSHA 1.53 -0.16(-9.47%)
Will TSHA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Other News for TSHA
Taysha Gene Therapies (TSHA) Gets a Buy from Cantor Fitzgerald
Optimism for Taysha Gene Therapies: Promising Preclinical Data and Upcoming Catalysts Drive Buy Rating
Taysha Gene Therapies to present biodistribution data from AAV9 analysis
Taysha Gene Therapies to present biodistribution data from AAV9 analysis
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data